Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of$ 0.26. This compares to loss of $0.20 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 19.23%. A quarter ago, it was expected that this molecular diagnostic company would post a loss of$ 0.29 per share when it actually produced a loss of $0.22, delivering a surprise of 24.14%.Over the last four quarters, th ...